GM-CSF as a target in inflammatory/autoimmune disease: current evidence and future therapeutic potential.

K/BxN Serum-Transfer Arthritis as a Model for Human Inflammatory Arthritis. Front Immunol (2016) 0.79

Anti-colony-stimulating factor therapies for inflammatory and autoimmune diseases. Nat Rev Drug Discov (2016) 0.77

GM-CSF and the role of myeloid regulatory cells in the pathogenesis and treatment of Crohn's disease. Mol Cell Pediatr (2015) 0.77

Granulocyte macrophage colony-stimulating factor induces CCL17 production via IRF4 to mediate inflammation. J Clin Invest (2016) 0.77

Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date. Drug Des Devel Ther (2017) 0.75

CSL311, a novel, potent, therapeutic monoclonal antibody for the treatment of diseases mediated by the common β chain of the IL-3, GM-CSF and IL-5 receptors. MAbs (2015) 0.75

GM-CSF and IL-3 Modulate Human Monocyte TNF-α Production and Renewal in In Vitro Models of Trained Immunity. Front Immunol (2017) 0.75

Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis. Arthritis Res Ther (2017) 0.75

Granulocyte macrophage colony-stimulating factor receptor α expression and its targeting in antigen-induced arthritis and inflammation. Arthritis Res Ther (2016) 0.75

The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression. Vaccines (Basel) (2016) 0.75